Core Viewpoint - Tian Tan Bio announced that its controlling shareholder, China National Biological Group Corporation, will transfer 18,802,366 shares (0.95% of total shares) to itself without compensation, resulting in China National holding 46.59% of the total shares post-transfer [1] Summary by Sections - **Share Transfer Details** - The transfer involves 18,802,366 shares from Beijing Biological Products Research Institute to China National [1] - After the transfer, China National will directly hold 921,302,854 shares, representing 46.59% of the total share capital [1] - **Ownership Structure Post-Transfer** - Beijing Biological Products Research Institute will no longer hold any shares in the company [1] - China National and its concerted parties will collectively hold 991,120,289 shares, maintaining a total ownership of 50.12% [1]

成大生物回复称，公司产品目前已覆盖30多个国家，主要包括泰国、埃及、印度等 "一带一路" 沿线国 家与地区，相关海外业务正稳步推进。关于您关注的欧盟国家，公司暂无产品出口至该区域。后续若海 外市场拓展有重要进展，公司将按规则及时履行披露。 格隆汇11月25日｜有投资者在互动平台向成大生物提问：了解到公司已出口30多个国家和地区，但是没 有披露具体国家，请问公司近两年(23/24年)是否有出口到欧盟国家呢？ ...

格隆汇11月25日丨成大生物(688739.SH)在投资者互动平台表示，公司产品目前已覆盖 30 多个国家，主 要包括泰国、埃及、印度等 "一带一路" 沿线国家与地区，相关海外业务正稳步推进。公司暂无产品出 口至欧盟国家区域。 ...

Group 1 - Dongbao Biological experienced a stock price increase of 7.04%, reaching 5.93 CNY per share, with a trading volume of 87.45 million CNY and a turnover rate of 2.63%, resulting in a total market capitalization of 3.52 billion CNY [1] - The company, founded on March 12, 1997, and listed on July 6, 2011, is located in Baotou, Inner Mongolia, and specializes in the research, production, and sales of gelatin products and low molecular weight collagen [1] - The main revenue composition of Dongbao Biological includes capsule business (54.13%), gelatin products and by-products (37.30%), collagen business (7.81%), organic fertilizer (0.53%), and others (0.22%) [1] Group 2 - Among the top ten circulating shareholders of Dongbao Biological, one fund from GF Fund Management, GF Jufeng Mixed A (270005), entered the list in the third quarter, holding 4.52 million shares, which accounts for 0.77% of the circulating shares [2] - The estimated floating profit for GF Jufeng Mixed A today is approximately 1.76 million CNY [2] - GF Jufeng Mixed A was established on December 23, 2005, with a current scale of 3.37 billion CNY, and has achieved a year-to-date return of 30.78%, ranking 1994 out of 8136 in its category [2]

Core Viewpoint - Shanghai Xinjixiang Biological Products Co., Ltd. has been established with a registered capital of 1 million RMB, focusing on various sales and technical services in the biomedical and electronic sectors [1] Company Overview - The legal representative of the company is Chen Yi [1] - The registered capital of the company is 1 million RMB [1] Business Scope - The company operates in general projects including sales of bio-based materials, medical devices (both Class I and Class II), electronic products, and computer hardware and software [1] - It also provides technical services, development, consulting, and information services, as well as conference and exhibition services [1] - The company is authorized to operate Class III medical devices, subject to approval from relevant authorities [1]

两融数据显示，该股最新融资余额为6.53亿元，近5日减少1146.23万元，降幅为1.73%。（数据宝） 11月24日微芯生物大宗交易一览 | 成交量 | 成交金额 | 成交价 | 相对当日收盘 | | | | --- | --- | --- | --- | --- | --- | | （万 | | 格 | | 买方营业部 | 卖方营业部 | | | （万元） | | 折溢价（%） | | | | 股） | | （元） | | | | | 25.00 | 589.75 | 23.59 | -13.24 | 中国银河证券股份有限公 | 国投证券股份有限公司深 | | | | | | 司南京洪武路证券营业部 | 圳宝安海秀路证券营业部 | | 24.00 | 566.16 | 23.59 | -13.24 | 华泰证券股份有限公司深 | 国投证券股份有限公司深 | | | | | | 圳后海中心路证券营业部 | 圳宝安海秀路证券营业部 | | 20.00 | 471.80 | 23.59 | -13.24 | 华泰证券股份有限公司南 | 国投证券股份有限公司深 | | | | | | 京文澜路证券营业部 | 圳宝 ...

Core Viewpoint - The company, Weilan Bio (603739), is currently in the early stages of developing synthetic biology products, with significant challenges ahead in terms of commercialization and industrialization [1] Group 1: Research and Development - The company has established a synthetic biology and biocatalysis technology center, which includes an innovation laboratory focused on developing functional proteins for feed and sweeteners for food [1] - The current R&D projects in the synthetic biology technology innovation laboratory are limited, with low investment amounts and insufficient professional personnel [1] - The laboratory is still in the preliminary strain research phase, indicating a considerable gap before achieving large-scale production [1] Group 2: Production Challenges - The production of synthetic biology products involves complex processes such as separation and purification, which the company currently lacks the capability to perform [1] - There are significant uncertainties regarding the commercialization of these products, which may also require regulatory approvals and market promotion, leading to a lengthy and challenging process [1] Group 3: Impact on Operations - The company anticipates that the current developments in synthetic biology will not have a significant impact on its operations in the foreseeable future [1] - The company will adhere to the disclosure obligations as per the Shanghai Stock Exchange regulations and will provide timely updates through official announcements [1]

（文章来源：证券日报） 证券日报网讯 11月24日晚间，热景生物发布公告称，近日，北京热景生物技术股份有限公司（以下简 称"公司"）获得了由中华人民共和国工业和信息化部（以下简称"工信部"）颁发的国家级专精特新"小 巨人"企业证书，入选工信部第七批国家级专精特新"小巨人"企业。 ...

Core Viewpoint - The company, Weilan Bio (603739.SH), currently lacks the necessary production processes for synthetic biology products, which involve complex separation and purification techniques, indicating significant challenges in commercialization [1] Group 1 - The production of synthetic biology products requires advanced separation and purification processes, which the company does not currently possess [1] - The purification process is noted to be particularly difficult, suggesting a need for further development before the company can effectively produce these products [1] - Future production may also involve regulatory approvals, product selection, and market promotion, all of which are expected to have long cycles and significant challenges, leading to major uncertainties in commercialization [1] Group 2 - The company anticipates that these challenges will not have a significant impact on its operations in the near term [1]

公司此次被认定为国家级专精特新"小巨人"企业，是对公司科研技术、创新能力、发展前景、产品质 量、行业地位等综合实力的充分认可，有利于提升公司的品牌知名度与核心竞争力，对公司整体业务发 展产生积极影响。 热景生物(688068.SH)发布公告，近日，公司获得了由中华人民共和国工业和信息化部(简称"工信部")颁 发的国家级专精特新"小巨人"企业证书，入选工信部第七批国家级专精特新"小巨人"企业。 ...